Navigation Links
Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs

MINNEAPOLIS/ST. PAUL (08/30/2013) A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found "online first" in the journal Antiviral Chemistry & Chemotherapy.

"If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn't want to have to take that medication via daily injection," said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. "This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation."

University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV's ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.

In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.

"There's still a lot of work that needs to be done to demonstrate the safety and efficacy of this drug combination before human clinical trials can begin," said Patterson. "But we're optimistic that we're moving forward."


Contact: Miranda Taylor
University of Minnesota Academic Health Center

Related biology news :

1. Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Research is ensuring stormwater systems are designed for the future
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
6. Portable diagnostics designed to be shaken, not stirred
7. MIT-designed cooler preserves tuberculosis drugs, records doses
8. Progress in Osteoporosis re-launched with new design, now invites commentary
9. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
10. SACLA draws acclaim for unique XFEL design
11. A new type of data papers designed to publish online interactive keys identifying biodiversity
Post Your Comments:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... -- Research and Markets ( ) has announced ... Market 2015-2019" report to their offering. ... voice recognition biometrics market to grow at a CAGR ... --> The report, Global Voice Recognition ... in-depth market analysis with inputs from industry experts. The ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):
(Date:11/28/2015)... South Korea (PRWEB) , ... November 28, 2015 , ... ... class of eco-friendly avian, porcine and rodent control solutions , ... as peppermint and cinnamon oil, works across all sensory modalities including visual, smell, taste ...
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology: